Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 179

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 179
---
 follows (in thousands):Three Months EndedNine Months EndedSeptember 30,September 30,2025202420252024Fixed lease costs$3,139 $3,459 $9,673 $10,416 Variable lease costs642 562 1,757 1,345 Sublease income— (56)(76)(248)Total$3,781 $3,965 $11,354 $11,513 Supplemental cash flow information related to operating leases is as follows (in thousands):Nine Months EndedSeptember 30,20252024Cash paid for operating lease liabilities, net of lease incentives$9,650 $9,686 Right-of-use assets recorded in exchange for lease obligations$2,043 $— The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:September 30,20252024Weighted average remaining lease term4.56 years5.36 yearsWeighted average discount rate6.91 %6.99 %

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  15

Maturities of the Company’s operating lease liabilities are as follows (in thousands):YearAggregate MinimumPayments Due2025 (remaining three months)$3,198 202612,789 202712,336 202811,188 202911,076 Thereafter6,384    Total future lease payments56,971    Less: imputed interest(8,384)   Total operating lease liabilities$48,587 

NOTE 8—GOODWILL AND INTANGIBLE ASSETS

GoodwillThe Company’s goodwill arose from the GQ Bio Acquisition in February 2025. As discussed below, the Company previously had goodwill resulting from the acquisition of Pacira Pharmaceuticals, Inc. (the Company’s California operating subsidiary) from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc, a subsidiary of Molex Asia Holdings Ltd.) in 2007, the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021